Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/aging.103988 http://scihub22266oqcxt.onion/10.18632/aging.103988 33031060!7732317!33031060     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33031060&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Aging+(Albany+NY) 2020 ; 12 (19): 18878-18888 Nephropedia Template TP {{tp|p=33031060|t=2020. Efficacy and safety of tocilizumab in COVID-19 patients |pdf=|usr=}}{{33031060}} gab.com Text Efficacy and safety of tocilizumab in COVID-19 patients JO: Aging (Albany NY) http://www.kidney.de/pget.php?&tw=1&pmid=33031060 #FOAvip In this retrospective study we assessed the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19). We enrolled 181 patients admitted to Huoshenshan Hospital (Wuhan, China) with confirmed COVID-19 between January 2020 and February 2020. Ninety-two patients were treated with tocilizumab, and 89 patients were treated conventionally. We analyzed the clinical manifestations, changes in CT scan images, and laboratory tests before and after tocilizumab treatment, and compared these results with the conventionally treated group. A significant reduction in the level of C-reactive protein was observed 1 week after tocilizumab administration. In some cases this meant the end of the IL-6-related cytokine storm. In addition, tocilizumab relieved fever, cough, and shortness of breath with no reported adverse drug reactions. These findings suggest tocilizumab improves clinical outcomes and is effective for treatment of patients with critical or severe COVID-19. However, future clinical trials are needed to better understand the impact of tocilizumab interference with IL-6 and provide a therapeutic strategy for treatment of COVID-19. Twit Text FOAVip Efficacy and safety of tocilizumab in COVID-19 patients ????Aging (Albany NY) http://www.kidney.de/pget.php?&tw=1&pmid=33031060 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33031060 #FOAvip English Wikipedia <ref>{{Cite pmid|33031060}}</ref> Efficacy and safety of tocilizumab in COVID-19 patients #MMPMID33031060 Zheng KL; Xu Y; Guo YF; Diao L; Kong XY; Wan XJ; Zhao F; Ning FZ; Wang LB; Qiao F; Zhao JM; Zhou JH; Zhong YQ; Wu SX; Chen Y; Jin G; Dong YC Aging (Albany NY) 2020[Oct]; 12 (19): 18878-18888 PMID33031060show ga In this retrospective study we assessed the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19). We enrolled 181 patients admitted to Huoshenshan Hospital (Wuhan, China) with confirmed COVID-19 between January 2020 and February 2020. Ninety-two patients were treated with tocilizumab, and 89 patients were treated conventionally. We analyzed the clinical manifestations, changes in CT scan images, and laboratory tests before and after tocilizumab treatment, and compared these results with the conventionally treated group. A significant reduction in the level of C-reactive protein was observed 1 week after tocilizumab administration. In some cases this meant the end of the IL-6-related cytokine storm. In addition, tocilizumab relieved fever, cough, and shortness of breath with no reported adverse drug reactions. These findings suggest tocilizumab improves clinical outcomes and is effective for treatment of patients with critical or severe COVID-19. However, future clinical trials are needed to better understand the impact of tocilizumab interference with IL-6 and provide a therapeutic strategy for treatment of COVID-19. äEfficacy and safety of tocilizumab in COVID-19 patients (epmc).pdf DeepDyve Pubget Overpricing